Want to see CRVO full AI Analyst Report?
Top Page
CervoMed
(NASDAQ:CRVO)
Select Model
Select Model
Rating:46Neutral
Price Target:
$2.50
▼(-5.66% Downside)
Action:Reiterated
Date:09/29/26
The score is held down primarily by weak financial performance (minimal revenue, large losses, and heavy cash burn), with technicals also showing a pressured longer-term trend. Positive corporate events around neflamapimod development and regulatory progress provide some offset, but they do not yet overcome the current profitability and funding-risk profile.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet reduces interest and refinancing pressure while preserving flexibility to fund clinical programs. Positive equity and a meaningful asset base provide some financial support as CervoMed advances development, although this benefit depends on managing ongoing cash use.
Negative Factors
Minimal commercial revenue and large losses
CervoMed remains dependent on clinical development rather than a commercial revenue base, so current operating costs substantially exceed internally generated income. Large recurring losses reduce financial resilience and make future progress dependent on successful development, commercialization, or additional funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet reduces interest and refinancing pressure while preserving flexibility to fund clinical programs. Positive equity and a meaningful asset base provide some financial support as CervoMed advances development, although this benefit depends on managing ongoing cash use.
Read all positive factors
CervoMed (CRVO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$45.66M
Dividend YieldN/A
Average Volume (3M)178.00K
Price to Earnings (P/E)―
Beta (1Y)-0.69
Revenue Growth-95.74%
EPS Growth-23.18%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.21
Shares Outstanding15,119,096
10 Day Avg. Volume210,661
30 Day Avg. Volume178,003
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)3.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.05
Enterprise Value/Market Cap0.15
Enterprise Value/Revenue21.14
Enterprise Value/Gross Profit21.14
Enterprise Value/Ebitda-0.22
Forecast
1Y Price Target
$15.50Price Target Upside484.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.15
Revenue Forecast (FY)$266.67K
CervoMed Business Overview & Revenue Model
Company Description
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that cro...
How the Company Makes Money
CervoMed does not have publicly established, material recurring revenue from marketed products; as a clinical-stage biotechnology company, it generally does not generate significant product sales prior to regulatory approval and commercialization....
CervoMed Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 322.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 322.57K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -30.35M | -26.97M | -16.29M | -2.17M | -5.80M | -15.94M |
| Net Income | -30.35M | -26.97M | -16.29M | -2.17M | -5.80M | -24.10M |
Balance Sheet | ||||||
| Total Assets | 25.99M | 23.40M | 43.08M | 9.97M | 4.16M | 37.84M |
| Cash, Cash Equivalents and Short-Term Investments | 24.94M | 20.86M | 38.92M | 7.79M | 4.09M | 37.31M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 12.41M | 0.00 |
| Total Liabilities | 3.03M | 5.18M | 3.88M | 2.60M | 13.16M | 2.93M |
| Stockholders Equity | 22.96M | 18.22M | 39.20M | 7.38M | -9.00M | 34.91M |
Cash Flow | ||||||
| Free Cash Flow | -27.98M | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Operating Cash Flow | -27.98M | -23.45M | -16.53M | -7.45M | -2.57M | -14.50M |
| Investing Cash Flow | 23.19M | 18.10M | -28.66M | 0.00 | 0.00 | 4.00K |
| Financing Cash Flow | 18.93M | 4.59M | 46.40M | 11.15M | 0.00 | 33.30M |
CervoMed Technical Analysis
Positive
2.65
Price Trends
2.65
Positive
2.94
Positive
4.05
Negative
Market Momentum
0.07
Negative
67.83
Neutral
87.02
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRVO, the sentiment is Positive. The current price of 2.65 is above the 20-day moving average (MA) of 2.60, below the 50-day MA of 2.65, and below the 200-day MA of 4.05, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 67.83 is Neutral, neither overbought nor oversold. The STOCH value of 87.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CRVO.
CervoMed Risk Analysis
CervoMed disclosed 75 risk factors in its most recent earnings report. CervoMed reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CervoMed Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $280.59M | -2.36 | -63.05% | ― | -51.65% | 91.93% | |
48 Neutral | $18.81M | -0.36 | -618.87% | ― | ― | 73.74% | |
47 Neutral | $292.88M | -4.65 | -75.35% | ― | 220.34% | 55.73% | |
46 Neutral | $45.66M | -0.94 | -156.02% | ― | -95.74% | -23.18% | |
42 Neutral | $26.96M | -3.42 | -71.47% | ― | -100.00% | -55.90% |
* Healthcare Sector Average
CRVO
CervoMed
3.02
-5.60
-64.97%
XFOR
X4 Pharmaceuticals
2.83
-0.54
-16.02%
ABVC
ABVC BioPharma
1.01
-2.12
-67.73%
JSPR
Jasper Therapeutics
0.57
-1.84
-76.46%
PRLD
Prelude Therapeutics
3.67
2.21
151.37%
ESLA
Estrella Immunopharma
0.47
-0.93
-66.57%
CervoMed Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
CervoMed Advances Neflamapimod Tablet and Dosing Strategy
Positive
Sep 28, 2026
On September 28, 2026, CervoMed reported new pharmacokinetic, regulatory, and manufacturing advances for neflamapimod, including a 50 mg oral tablet that uses a more stable crystalline form and a controlled process intended to support consistent l...
Business Operations and Strategy
CervoMed highlights late-breaking neflamapimod Phase 2a data
Positive
Sep 10, 2026
On September 10, 2026, CervoMed announced that initial results from its Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia have been accepted for a late-breaking oral presentation at the International Society of Fronto...
Business Operations and StrategyRegulatory Filings and Compliance
CervoMed’s neflamapimod gains UK Innovation Passport
Positive
Aug 4, 2026
On August 4, 2026, CervoMed announced that neflamapimod, its oral small-molecule drug targeting neuroinflammation in degenerative brain disorders, was granted an Innovation Passport under the United Kingdom’s Innovative Licensing and Access ...
Business Operations and Strategy
CervoMed advances neflamapimod strategy with new DLB data
Positive
Jul 15, 2026
On July 14, 2026, CervoMed reported new clinical, plasma biomarker and imaging data for neflamapimod in dementia with Lewy bodies at the Alzheimer’s Association International Conference in London, highlighting analyses from the 159-patient P...
Business Operations and StrategyProduct-Related Announcements
CervoMed Completes Enrollment in Phase 2a Neflamapimod Trial
Positive
Jul 9, 2026
On July 9, 2026, CervoMed Inc., a clinical-stage biotechnology company developing oral small-molecule therapies for age-related brain disorders, said it has completed enrollment in its Phase 2a trial of lead candidate neflamapimod in nonfluent var...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.